alexa Functional Respiratory Imaging (FRI) To Assess Bio-equivalence Of Inhaled Medication
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Jan De Backer
ScientificTracks Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851.S1.017
D emonstrating bio-equivalence of inhaled drugs is challenging. The conventional pharmacodynamics (PD) endpoints often lack the sensitivity to differentiate between different products while the pharmacokinetic (PK) endpoints are usually too sensitive and subject to batch to batch variability. Functional Respiratory Imaging (FRI) is a novel imaging biomarker used in respiratory drug development, which has the potential to bridge between PD and PK measures. FRI consists of a combination of high resolution computed tomography (HRCT) imaging and computational fluid dynamics (CFD). While the HRCT provides structural information of the respiratory system, CFD yields functional characteristics such as resistances and aerosol deposition characteristics. This study demonstrates that by providing regional characteristics of the airway volumes, airway resistances and aerosol deposition, FRI has an increased sensitivity to differentiate between products. Two examples will be shown, one cross over study between salbutamol and ipratropium bromide in COPD patients and a cross over study using Fluticasone Salmeterol (branded versus generic) in asthma patients. These cases demonstrate that when products are different, unlike the conventional PD measures, FRI can differentiate the two. When products are equivalent, FRI yields additional evidence supporting the claims. In addition when test and reference products are not equivalent, FRI allows identifying the cause (inhalation profile, aerosol deposition, etc) that can lead to product optimization. While still being a novel method, FRI has proven to be very useful in drug development for innovator products and the first results demonstrate a large potential in the field of bio-equivalence.
Jan De Backer graduated from Delft University of Technology, The Netherlands as aerospace engineer. He attained an MSc degree in Aerodynamics and specialized in applied biomedical computational fluid dynamics leading to a PhD from the University of Antwerp, Belgium. He is an alumnus of the MBA programs at London Business School, London and Columbia Business School, New York. He has received several awards for his innovative research and his work has been published in international journals. He founded FLUIDDA in 2005 and holds the position as Chief Executive Officer since 2007.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version